Edison Investment Research

Renewi (RWI); completes strategic exit from UK organics with sale of Cumbernauld facility

Stock up 0.30% to 63.19p at 8:39

RWI, in line with its stated strategy to actively manage the business portfolio, sold its 50% share in the Energen Biogas (EBG) facility in Cumbernauld to Bio Capital (owned by Helios, Equitix and Aurium Capital).

Polypipe Group (PLP); acquisition of Permavoid for initial cash consideration of £4.0m

Stock down 0.20% to 369.26p at 8:24

PLP has announced the acquisition of Permavoid Limited (Permavoid) for an initial cash consideration of £4.0m. It also announced a further deferred consideration of up to £12.5m depending on the EBITDA performance of Permavoid in the two years to 30 September 2020.

Princess Private Equity Holding (PEY); announced directorate change

Stock flat at €10.20 at 08:13

PEY announced that Brian Human has stepped down as chairman with effect from 1 September 2018. However, he will continue to serve as director until the end of November 2018. Mr. Human will be succeeded as chairman by Richard Battey.

Future (FUTR); trading update: cash conversion remains excellent

Stock up 6.01% to 450p at 08:16

FUTR reported a pre-close trading update for the 12 months to 30 September 2018. Trading for the year in FUTR’s core operations has been stronger than the board’s previous expectations. It continues to show good revenue growth in all the core areas.

WANdisco (WAND); 1H 2018 trading update: secures three new Microsoft deals

Stock down 2.62% to 930.0p at 8:10

Total bookings for the six months ended 30 June 2018 decreased to $9m from $10.2m for the previous corresponding period. Big Data bookings secured for WANdisco Fusion fell to $6.2m (H1 2017: $7.0m) and Source Code Management bookings dropped to $2.8m ($3.2m).

Not a great weak for pharma as AstraZeneca and Pfizer reported a set of unsuccessful trials

As big pharmaceutical companies continue to encroach on the traditional biotech company space of orphan drugs and difficult-to-treat diseases, Pfizer and AstraZeneca have learned this week that it is not as easy as they may have thought.

Restaurant Group posts pre-tax profit of $20.1m with a like-for-like sales decline of 3.7%

Now halfway through its third year of attempted turnaround, Restaurant Group’s interim result was always going to be down on last year. Like-for-like sales decline of 3.7% was actually no worse than expected following indications of a slight improvement against -4.3% for the first 20 weeks.

Share (SHRE); Q2 2018 revenue market share increases to 3.88% from 3.54% in the Q1 2018

SHRE’s market share by revenue for Q2 2018, relative to a peer group of 15 other UK retail stockbrokers*, as measured by Compeer Limited, increased to 3.88% from 3.54% in Q1 2018.

EMIS Group (EMIS); 1H18 results: strong cash flow performance

Stock up 4.26% to 954.00p at 08:02

For the six months ended 30 June 2018, revenue increased by 7% (completely organic) to £84.5m (1H17: £79.2m). Adjusted operating profit for the period was £17.6m (1H17: £17.5m), while adjusted basic and diluted EPS were unchanged at 22.2p and 22.1p, respectively.

Hutchison China Meditech (HCM); 66,535,683 ordinary shares in issue

HCM has announced that the total issued share capital of the company is 66,535,683 ordinary shares of $1.00 each with each share carrying one vote and no shares held in treasury.